Fractyl Health Inc. Commo... (GUTS)
1.11
-0.03 (-2.63%)
At close: Apr 04, 2025, 3:59 PM
1.17
5.41%
After-hours: Apr 04, 2025, 05:44 PM EDT
-2.63% (1D)
| Bid | 1.05 |
| Market Cap | 54.3M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.62 |
| PE Ratio (ttm) | -0.69 |
| Forward PE | -0.78 |
| Analyst | Buy |
| Ask | 1.21 |
| Volume | 188,363 |
| Avg. Volume (20D) | 295,331 |
| Open | 1.11 |
| Previous Close | 1.14 |
| Day's Range | 1.07 - 1.14 |
| 52-Week Range | 1.07 - 7.89 |
| Beta | 0.30 |
About GUTS
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform ...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 107
Stock Exchange NASDAQ
Ticker Symbol GUTS
Website https://fractyl.com
Analyst Forecast
According to 1 analyst ratings, the average rating for GUTS stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 800.90% from the latest price.
Stock Forecasts5 months ago
+16.46%
Fractyl Health shares are trading higher after the...
Unlock content with
Pro Subscription
